These results highlight that aberrant astrocytic Mysm1 functions as a potential molecular mechanism underlying MDD pathophysiology, and suggest that astrocytic Mysm1 could serve as a potential target for new therapeutic interventions against depressive disorders. The gene discussed is MYSM1; the disease is depressive disorder.